Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 1

Interventions

Cisplatin 7Pemetrexed 6atezolizumab 5Carboplatin 4tislelizumab 3Paclitaxel 3Leucovorin 3Filgrastim 3Etoposide 3vistusertib 2pembrolizumab 2Vincristine 2Topotecan 2Temozolomide 2Tegafur 2Sorafenib 2Irinotecan 2Immunoenzyme Techniques 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2zirconium-89-trastuzumab 1vandetanib 1toripalimab 1temsirolimus 1tanespimycin 1talazoparib 1soblidotin 1selinexor 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × navoximod × Other solid neoplasm × Clear all
NCT05469490 2022-09-30

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

University of Pittsburgh

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡